A 68-year-old man with COPD presents with community-acquired pneumonia (CAP). Regarding the empirical antibiotic therapy for CAP in this patient, all of the following are appropriate EXCEPT:

## Empirical Antibiotic Therapy for CAP — Appropriate Regimens **Key Point:** Vancomycin monotherapy is NOT appropriate for CAP because it lacks coverage of atypical organisms (Mycoplasma, Chlamydia, Legionella) and gram-negative enteric bacteria — both common CAP pathogens. Vancomycin is reserved for specific indications (e.g., MRSA suspected, severe allergy to beta-lactams) and MUST be combined with other agents for broad coverage. ### Appropriate Empirical Regimens for CAP | Clinical Setting | Recommended Regimen | Rationale | | --- | --- | --- | | Outpatient, no comorbidity | Amoxicillin-clavulanate OR respiratory fluoroquinolone | Covers S. pneumoniae, H. influenzae, atypicals | | Outpatient, with comorbidity (COPD, diabetes) | Respiratory fluoroquinolone monotherapy | Broad spectrum: S. pneumoniae, H. influenzae, atypicals, gram-negatives | | Hospitalized, non-severe | Beta-lactam (ceftriaxone) + macrolide | Covers S. pneumoniae, H. influenzae, atypicals | | Hospitalized, severe / ICU | Beta-lactam + fluoroquinolone OR beta-lactam + macrolide ± vancomycin (if MRSA risk) | Broad coverage; vancomycin added only if MRSA suspected | **High-Yield:** In this patient (COPD, age >65), a respiratory fluoroquinolone monotherapy OR beta-lactam + macrolide is preferred. Vancomycin monotherapy is inadequate because: 1. **No atypical coverage** — Mycoplasma, Chlamydia, Legionella are not covered. 2. **No gram-negative coverage** — Enterobacteriaceae and Pseudomonas (if risk factors present) are not covered. 3. **Vancomycin is reserved for specific indications** — MRSA suspicion, severe beta-lactam allergy, or meningitis. **Clinical Pearl:** When vancomycin IS used in CAP (e.g., suspected MRSA), it must ALWAYS be combined with a fluoroquinolone or macrolide for atypical coverage, or with a beta-lactam for broader gram-negative coverage. ### Why Each Distractor Is Correct - **Amoxicillin-clavulanate monotherapy (outpatient):** Appropriate for outpatient CAP without comorbidity; covers S. pneumoniae and H. influenzae; atypical coverage less critical in mild disease. - **Respiratory fluoroquinolone monotherapy:** Excellent choice for outpatient or hospitalized CAP; covers all major CAP pathogens including atypicals and gram-negatives. - **Beta-lactam + macrolide (hospitalized):** Gold standard for hospitalized CAP; covers S. pneumoniae, H. influenzae, and atypicals.